High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.

Adam B WeinerChristina Y YuMitali KiniYang LiuElai DavicioniAntonina MitrofanovaTamara L LotanEdward M Schaeffer

Published in: Prostate cancer and prostatic diseases (2022)

Markers of plasma cell activity might be leveraged to augment clinical trial targeting and selection and better understand the potential for immune-based treatments in patients with PCa at a high risk of recurrence following local treatment.

Keyphrases

prostate cancer
clinical trial
induced apoptosis
radical prostatectomy
single cell
cell cycle arrest
human health
cell therapy
risk assessment
endoplasmic reticulum stress
bone marrow
mesenchymal stem cells
oxidative stress
cell death
drug delivery
signaling pathway
double blind
pi k akt